ApoB

Apolipoprotein B (apoB) is a blood test that counts the cholesterol-carrying particles that build plaque, instead of weighing the cholesterol inside them. It predicts cardiovascular risk at least as well as LDL cholesterol, and better when the two disagree, which happens more often than most people assume. That acting on apoB rather than LDL cholesterol improves outcomes is less certain: it rests on observational studies.

For a baseline workup, an apoB test probably tells you more than the LDL cholesterol on the same panel. If you are already on treatment and have reached your LDL and non-HDL cholesterol goals, apoB helps decide whether to push further, especially with heart disease, type 2 diabetes or high triglycerides.

One protein per particle

Every particle that can build plaque — low-density lipoprotein (LDL), intermediate-density lipoprotein (IDL), very-low-density lipoprotein (VLDL) and lipoprotein(a) — carries exactly one molecule of apoB on its surface. Measuring apoB in the blood therefore gives a direct count of how many of these particles are circulating. LDL cholesterol (LDL-C), the standard number, measures only the cholesterol mass inside one subset of them, and the amount of cholesterol per particle varies considerably from person to person.^[1]

When particles are smaller, denser and depleted of cholesterol — as in metabolic syndrome, insulin resistance and some genetic patterns — LDL-C can look reassuring while the particle count is high. That count is what matters, because plaque builds from particles trapped in the artery wall, in proportion to how many you have had and for how long; see Lipid management.

Test	What it measures	When it matters most
LDL-C	Cholesterol mass inside LDL particles	Standard target; everywhere, cheap, well understood
Non-HDL-C	Cholesterol in all plaque-building particles (total cholesterol minus high-density lipoprotein, HDL, cholesterol)	Useful when triglycerides are high; doesn't count particles
ApoB	Number of plaque-building particles	The best measure of particle burden when LDL-C and apoB disagree

The numbers disagree more often than assumed

In a national US survey of 12,688 adults, people with a standard LDL-C of 100 mg/dL had a median apoB of 80 mg/dL — but 95% of them fell anywhere between 66 and 99 mg/dL. A higher-than-expected apoB was more common in people with metabolic risk factors, but it wasn't restricted to them: apoB varied widely at any given LDL-C even in metabolically healthy adults (normal weight, triglycerides under 150 mg/dL, no diabetes). Non-HDL cholesterol tracked apoB more closely than LDL-C did.^[2]

A UK study of 375,544 adults showed what the mismatch costs. About one in five had an apoB that clearly disagreed with their LDL-C, and in half of them apoB was the higher number. In those people, the risk of major cardiovascular events ran about 6–11% higher, depending on how fully the analysis adjusted for other factors (6% after accounting for triglycerides, HDL cholesterol and Lp(a)), regardless of their LDL-C level. Particles rich in triglycerides (VLDL) and triglycerides themselves each explained about a quarter of the extra risk, and the authors concluded it was driven mainly by the number of apoB-carrying particles.^[3] Both studies are observational: they show apoB predicts risk, not that treating to apoB prevents events.

Better than LDL-C; unclear against non-HDL cholesterol

ApoB predicts heart risk more reliably than LDL-C. In a pooled analysis of 12 studies covering about 233,000 people, apoB was the strongest of the three markers and LDL-C the weakest.^[4]

Whether it also beats non-HDL cholesterol, which comes free with any standard panel, is less clear. In 94,398 Danish adults not taking cholesterol-lowering drugs, the two predicted heart attacks and other artery-disease events about equally well, and each added some information beyond the other.^[5] In nearly 300,000 UK Biobank adults, by contrast, once apoB was in the model the extra risk carried by LDL-C, non-HDL cholesterol and triglycerides all vanished.^[6]

Not every particle is equally harmful either: genetic evidence suggests the larger triglyceride-rich remnant particles are roughly four times as damaging per particle as LDL.^[7]

Where the guideline puts it

The 2026 US cholesterol guideline (from the American College of Cardiology and American Heart Association, ACC/AHA) keeps LDL-C and non-HDL-C as the main targets and gives apoB a supporting role. For people on lipid-lowering treatment, measuring it is "reasonable" once their LDL-C and non-HDL-C goals are met, to decide whether to intensify — especially with cardiovascular disease, cardiovascular-kidney-metabolic syndrome, type 2 diabetes or high triglycerides. Before treatment, it "may be reasonable" to refine risk.^[8] The guideline's own summary singles out triglycerides above 200 mg/dL, diabetes and an already low LDL-C (below 70 mg/dL) as the situations where it helps most.^[9] The apoB goals that different guidelines set by risk level are compared in Midlife labs.

Why particles, not cholesterol, are the target

Drugs that clear apoB-carrying particles by different routes produce benefit in proportion to how far they lower them. Not every cholesterol drug qualifies, though: one drug, evacetrapib, cut LDL-C by about 31% and prevented no events,^[10] and genetic evidence suggests benefit follows the fall in apoB particles rather than in LDL cholesterol as such.^[11] That supports counting particles; it still isn't a trial of treating to an apoB number.

What to do

Add apoB to your next lipid panel; it belongs on the yearly midlife lab panel.
Don't take a normal LDL-C as the whole answer, especially with insulin resistance, high triglycerides or diabetes, where a high particle count hides most often.
On treatment and at your LDL-C and non-HDL-C goals? Ask whether an apoB result should change the plan, particularly if you have heart disease, diabetes or high triglycerides.